The first approved CRISPR medicine has now shown similarly strong results in children as young as five years old with sickle cell disease and...
Alpha-1 antitrypsin deficiency (AATD) has turned into the most crowded proving ground in genetic medicine, with five editing companies reporting fresh...
Intellia Therapeutics has initiated a rolling biologics license application (BLA) with the U.S. Food and Drug Administration for lonvoguran ziclumeran...
The US FDA has issued a Study May Proceed notification for PBGENE-DMD, Precision BioSciences' investigational in vivo gene-editing therapy for...
On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based...
iECURE's ECUR-506 has secured both the US FDA Regenerative Medicine Advanced Therapy designation and a UK Innovation Passport, positioning the...
A first-in-human, phase I trial tested intrathecal delivery of CRISPR-Cas9-edited, allogeneic IL-13Rα2 CAR-T cells in five people with recurrent...
nChroma Bio has received regulatory clearance in Hong Kong to initiate a Phase 1/2 clinical trial of its lead candidate CRMA-1001, marking the first...
